Nicergoline
Sermion — an ergoline derivative of nicotinic acid
Nicergoline (Sermion — an ergoline derivative of nicotinic acid) is a cognitive & mood research compound. An ergot alkaloid carrying a nicotinic acid ester, marketed for fifty years on alpha-1 adrenoceptor blockade and the cerebral blood flow that is supposed to follow. The most recent receptor work on it points somewhere else entirely: a 2024 study of the human 5-HT3A receptor found nicergoline blocking it, characterized the binding and the residues involved, and that is a different pharmacology from vasodilation. It is hydrolyzed rapidly to a metabolite that carries most of the exposure, so the parent's own half-life describes almost nothing about the drug's duration.
Nicergoline quick facts
| Route | Oral |
| Frequency | Per prescription · Per prescription |
| Half-life | Parent ~2.5 hrs; the major metabolite carries the exposure and lasts far longer |
| Forms | Oral |
| Evidence level | A prescription medicine in much of Europe and Asia; never approved in the United States. Its efficacy claims sit in vascular dementia network meta-analyses. |
The interesting thing about this drug is that its best-established action and its selling proposition are not the same. It has been sold as a cerebral vasodilator since the 1970s; the sharpest modern measurement of it is receptor blockade at 5-HT3A. It is also an ergoline, and the ergoline scaffold is the one that produced valve and retroperitoneal fibrosis in the drugs that agonize 5-HT2B — a class hazard that belongs on the page whether or not it has been demonstrated for this particular member. Prescription-only, no buy route here.
How Nicergoline works
An ergot alkaloid carrying a nicotinic acid ester, marketed for fifty years on alpha-1 adrenoceptor blockade and the cerebral blood flow that is supposed to follow. The most recent receptor work on it points somewhere else entirely: a 2024 study of the human 5-HT3A receptor found nicergoline blocking it, characterized the binding and the residues involved, and that is a different pharmacology from vasodilation. It is hydrolyzed rapidly to a metabolite that carries most of the exposure, so the parent's own half-life describes almost nothing about the drug's duration.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get Nicergoline
Buy Nicergoline at RUPharma →A prescription ergoline in Europe and Asia, never approved in the United States — so there is no FDA label behind it and no American adverse-reaction table to quote.
It is a vasodilator and an alpha-1 blocker, so the reliable effect is a drop in blood pressure — a cuff at home tells you more in a week than any panel. The ergoline scaffold's fibrosis history is the reason a prescriber, not a checkout, should be the one deciding on long runs.
Order these through my Marek link →The evidence for Nicergoline
Graded by what exists behind each claim.
✅ Clinically validated
- A prescription medicine in much of Europe and Asia and never approved in the United States, so there is no FDA label and no American adverse-reaction table behind any claim made for it.
- Its efficacy claim sits in vascular dementia — a systematic review and Bayesian network meta-analysis of pharmacological treatments for that condition (Dang 2024). An older European and Asian literature, pooled indirectly, in diagnosed cerebrovascular patients.
📊 Correlative data
- The most modern receptor measurement of it is blockade of the human 5-HT3A receptor (Pyeon 2024) — a ligand-gated ion channel and the target of the anti-nausea drugs. That is not vasodilation and not adrenergic.
- It is catalogued among cognitive enhancers with doses and side effects (Malik 2022). Being catalogued is not being demonstrated.
🧪 Theoretical / extrapolated
- It is an ergoline. The documented cardiac harm in that family is valvular and retroperitoneal fibrosis driven by 5-HT2B agonism (Rouaud 2024). Nobody has published nicergoline's affinity at 5-HT2B, which is a single binding assay and a remarkable gap for a drug this old.
- It is hydrolyzed rapidly and its metabolites carry most of the exposure, so a receptor profile measured on the parent describes a species that is barely present in a treated person.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Nicergoline actually does
The molecule is two things bolted together, and the market only talks about one of them. Nicergoline is an ergoline — the tetracyclic scaffold shared by ergotamine, bromocriptine, cabergoline and lysergic acid derivatives — carrying a nicotinic acid ester. It has been sold since the 1970s on alpha-1 adrenoceptor blockade and the increase in cerebral blood flow that was expected to follow.
The most modern measurement of it points somewhere else. Pyeon 2024 studied the molecular mechanism by which nicergoline blocks the human 5-HT3A receptor, a ligand-gated ion channel and the target of the anti-nausea drugs. That is not vasodilation and it is not adrenergic. It is a specific, characterized action at a specific channel, published in 2024, on a drug that has been marketed for half a century on a different premise.
Why the scaffold matters more than the substitution. The documented cardiac harm in the ergoline family is fibrosis of heart valves and retroperitoneal tissue, and the mechanism identified for it is agonism at 5-HT2B receptors, which drives fibroblast proliferation. Rouaud 2024 is a comparison of psychedelic microdosing against known cardiotoxins built on exactly that receptor logic. A page about any ergoline that omits 5-HT2B is omitting the class's defining hazard, whether or not it has been demonstrated for this particular member.
The pro-drug problem, stated plainly. Nicergoline is hydrolyzed rapidly after absorption, and its major metabolites carry most of the systemic exposure. So the parent's receptor profile and the drug's clinical behavior are not the same subject, and any mechanism argued from a receptor assay on the parent molecule Pyeon 2024 is an argument about a species that is not present for long.
Cell, rodent, human — and where it stops
Where its efficacy claim actually sits. Dang 2024 is a systematic review and Bayesian network meta-analysis of pharmacological treatments for vascular dementia. That is the setting in which this drug's evidence lives: an older European and Asian literature, in cerebrovascular cognitive impairment, pooled indirectly because head-to-head trials are scarce. It is a real evidence base and it is not an evidence base about healthy cognition.
What the nootropic literature does with it. Malik 2022 catalogs cognitive enhancers with their doses and side effects and includes this class. Being catalogued is not being demonstrated, and the distinction matters here more than usual because the retail market for this drug is people with no cerebrovascular diagnosis at all.
The regulatory fact that frames everything else. It is a prescription medicine in much of Europe and Asia and has never been approved in the United States. There is therefore no FDA label to read, no US adverse-reaction table, and no American prescribing information behind any claim made for it. Where a page would normally quote a regulator, this one has nothing to quote.
The delivery literature says something about the oral route without meaning to. Abourehab 2021 develops sesame-oil-based nanostructured lipid carriers for intranasal nicergoline aimed at brain targeting. Formulation scientists build nose-to-brain systems for molecules whose oral delivery to the brain is unsatisfying. That is an indirect signal and it is worth reading as one.
Nicergoline pharmacokinetics — how much of it actually gets in
What degrades it. Rapid ester hydrolysis after absorption removes the nicotinic acid, and hepatic first-pass metabolism handles the rest, with cytochrome-mediated demethylation producing metabolites that carry most of the systemic exposure. The parent is largely gone before it has circulated, which is the defining pharmacokinetic fact about this drug and the reason its half-life is quoted so inconsistently.
The oral barrier. Absorption from the gut is good but first-pass extraction is extensive, so the bioavailability of the intact parent is low while total exposure to active material is not. That gap is precisely why Abourehab 2021 exists: an intranasal lipid carrier is an attempt to reach brain tissue without the liver taking its share first.
The numbers, with their uncertainty attached. The parent's plasma half-life is on the order of 2.5 hours while the major metabolite is far longer-lived, which is why dosing in the European literature is two or three times daily at a total around 30 mg and not once daily. A tablet strength of 10 to 30 mg spans that whole range in a single product line, which is a real practical hazard on a drug bought without a prescription.
The comparator, and why it is not available. Injectable nicergoline has been used in some markets, and any comparison between an injection and a tablet would isolate exactly how much the first pass takes. No such comparison resolves in the literature this page can read, so the size of the hepatic loss is inferred from the chemistry rather than measured.
What would have to be true, and how you would know it was not
Four predictions. This is a prescription medicine and two of these are surveillance rather than efficacy.
1. ESR and hs-CRP, because the class hazard is fibrotic. Retroperitoneal and pleuropulmonary fibrosis on ergolines classically presents with a raised erythrocyte sedimentation rate before it presents with anything a patient notices. Pairing it with hs-CRP is the standard inflammatory pair. Neither is specific, both are cheap, and on a drug from this scaffold they are the surveillance that matches the mechanism Rouaud 2024.
2. Echocardiography is the measurement that would actually settle valve safety, and nobody does it for this drug. The dopamine-agonist ergolines acquired routine echocardiographic monitoring after the valvulopathy signal emerged. Nicergoline never did, and the absence is not evidence of safety — it is evidence that the question was not asked of this member of the family.
3. Standing blood pressure, not seated. Alpha-1 blockade lowers vascular tone, and the predicted adverse effect is orthostatic — dizziness on standing, worst on the first dose and after any increase. A seated reading will miss it entirely. This is the one prediction on this page a reader can test in thirty seconds.
4. Against the product: the mechanism most recently measured predicts an anti-nausea effect rather than a cognitive one. If 5-HT3A blockade Pyeon 2024 is a real contributor at therapeutic concentrations, the noticeable subjective effects should look more like ondansetron than like a stimulant. That is a falsifiable statement about what people should report, and what people do report has never been collected systematically.
What nobody has tested yet
Nobody has run it in healthy adults. The evidence base is in cerebrovascular cognitive impairment Dang 2024. There is no randomized trial of nicergoline for cognition in people without a diagnosis, which is the entire retail market.
Nobody has looked for valvular fibrosis in nicergoline users. The pharmacovigilance work that found valve disease on pergolide and cabergoline was echocardiographic screening of exposed cohorts. The equivalent study has not been published for this drug, so the honest position is unmeasured rather than negative.
The receptor picture is incomplete in a specific way. Pyeon 2024 characterized 5-HT3A blockade. Nobody has published the affinity of nicergoline or its major metabolites at 5-HT2B, which is the receptor that determines whether the class hazard applies to this member. That is a single binding assay and its absence is remarkable for a drug this old.
Extrapolation, labeled as such. If most of the activity belongs to the metabolites rather than the parent, then every receptor study done on the parent describes a molecule that is barely present in a treated person. Repeating the 5-HT3A work on the major metabolite would either transfer the finding or retire it, and it has not been done.
Nicergoline — its own safety story, not its class's
Prescription-only, and with no United States approval at all. That combination is unusual and it has a practical consequence: there is no FDA label, so the adverse-reaction table a reader would normally consult does not exist in English from a regulator. The Vault carries no buy route for it, and nothing here is instruction for obtaining or using it without a prescriber.
The class hazard, named because it is the one that would matter. Ergoline derivatives are associated with fibrotic disease of heart valves, pleura and retroperitoneum, and the mechanism identified is 5-HT2B agonism driving fibroblast proliferation Rouaud 2024. Whether nicergoline shares it has not been settled either way. Naming an unmeasured class risk is the correct move; asserting that it applies would be as unsupported as asserting it does not.
The predicted acute effects follow from alpha-1 blockade. Orthostatic hypotension, dizziness on standing, nasal congestion and a fall in blood pressure that adds to any antihypertensive already being taken. The interaction that follows from that is arithmetic rather than exotic: two things lowering vascular tone lower it together.
Ergot alkaloids and vasoconstrictors are the combination to avoid, and it is the opposite of what people expect. The ergoline family's oldest toxicity is ergotism — intense peripheral vasoconstriction — and it is worsened by potent CYP3A4 inhibitors and by triptans. That this molecule is marketed as a vasodilator does not exempt its scaffold from the history of the family it belongs to.
Sources read for this page
- Pyeon M, Moon M, Yun J, Yang J, Yeom HD, Lee G, Lee JH. Molecular Mechanisms of Nicergoline from Ergot Fungus in Blocking Human 5-HT3A Receptor. Journal of Microbiology and Biotechnology 2024 · PMID 39849925
- Dang C, Wang Q, Zhuang Y, Li Q, Feng L, Xiong Y, Lu Y. Pharmacological treatments for vascular dementia: a systematic review and Bayesian network meta-analysis. Frontiers in Pharmacology 2024 · PMID 39239652
- Malik M, Tlustos P. Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs. Nutrients 2022 · PMID 36014874
- Rouaud A, Calder AE, Hasler G. Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins. Journal of Psychopharmacology 2024 · PMID 38214279
- Abourehab MAS, Khames A, Genedy S, Mostafa S, Khaleel MA, Omar MM, El Sisi AM. Sesame Oil-Based Nanostructured Lipid Carriers of Nicergoline, Intranasal Delivery System for Brain Targeting of Synergistic Cerebrovascular Protection. Pharmaceutics 2021 · PMID 33921796
Nicergoline — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Nicergoline moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Nicergoline in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Nicergoline
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Nicergoline — frequently asked questions
What is Nicergoline?
Nicergoline (Sermion — an ergoline derivative of nicotinic acid) is a cognitive & mood research compound. An ergot alkaloid carrying a nicotinic acid ester, marketed for fifty years on alpha-1 adrenoceptor blockade and the cerebral blood flow that is supposed to follow. The most recent receptor work on it points somewhere else entirely: a 2024 study of the human 5-HT3A receptor found nicergoline blocking it, characterized the binding and the residues involved, and that is a different pharmacology from vasodilation. It is hydrolyzed rapidly to a metabolite that carries most of the exposure, so the parent's own half-life describes almost nothing about the drug's duration.
Where can I find Nicergoline dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Nicergoline protocol are available to members inside Skool. This public page covers what Nicergoline is, how it works and the evidence.
What is the half-life of Nicergoline?
Nicergoline has an approximate half-life of Parent ~2.5 hrs; the major metabolite carries the exposure and lasts far longer, which is part of what determines how often it's dosed.
What's the evidence behind Nicergoline?
Current evidence level: A prescription medicine in much of Europe and Asia; never approved in the United States. Its efficacy claims sit in vascular dementia network meta-analyses.. Nicergoline is offered for research purposes only and is not an approved medicine.
What Nicergoline is used for
Nicergoline appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.